Literature DB >> 23484169

Brånemark system implants and rare disorders: a report of six cases.

Bertil Friberg1.   

Abstract

Rare disorders are conditions defined as either fatal or causing chronic functional impairment. There is limited evidence of the behavior of oral implants in patients suffering from such diseases, and the existing data are merely based on cases reports. This paper describes the outcome of implant treatment after up to 15 years of function in three patients afflicted with X-linked hypophosphatemia, two patients with Langerhans cell histiocytosis, and one patient with osteogenesis/dentinogenesis imperfecta.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23484169     DOI: 10.11607/prd.1429

Source DB:  PubMed          Journal:  Int J Periodontics Restorative Dent        ISSN: 0198-7569            Impact factor:   1.840


  5 in total

1.  Implant-supported fixed prostheses in a Patient with Osteogenesis Imperfecta: A 4-year follow-up.

Authors:  Mario Caicedo-Rubio; Elvira Ferrés-Amat; Eduard Ferrés-Padró
Journal:  J Clin Exp Dent       Date:  2017-12-01

2.  Implant therapy for a patient with osteogenesis imperfecta type I: review of literature with a case report.

Authors:  Shamit S Prabhu; Kevin Fortier; Michael C May; Uday N Reebye
Journal:  Int J Implant Dent       Date:  2018-11-23

3.  Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review.

Authors:  L Seefried; M Smyth; R Keen; P Harvengt
Journal:  Osteoporos Int       Date:  2020-07-24       Impact factor: 4.507

4.  Implant-Prosthetic Restoration of a Patient with Osteogenesis Imperfecta: A Case Report.

Authors:  Marcel Hanisch; Melanie Maus; Johannes Kleinheinz
Journal:  Int J Environ Res Public Health       Date:  2021-04-15       Impact factor: 3.390

Review 5.  Dental Implants in People with Osteogenesis Imperfecta: A Systematic Review.

Authors:  Ole Oelerich; Johannes Kleinheinz; Lauren Bohner; Vera Wiesmüller; Marcel Hanisch
Journal:  Int J Environ Res Public Health       Date:  2022-01-29       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.